Contact us Demo our platform

Blog

Real-Time Assessment of the Brain

assessment brain

“If the human brain were so simple that we could understand it, we would be so simple that we couldn’t.”  

This quote, attributed to the late physicist, Emerson M. Pugh, succinctly highlights the daunting challenges of neuroscience research. The complexity of the nervous system lies not only in its structure but also in its functions and interactions. It is a system that controls our memories, emotions, behaviors, and movements, with a biological architecture comprising billions of neurons, glia, and non-neural cells. These cells form trillions of dynamic connections which do not act in isolation, rather they are constantly responding to signals emanating from throughout the body. Additionally, each cell body, axon, and dendrite contain a variety of intracellular signaling pathways which, in turn, are modulated by hundreds of neurotransmitters, neuropeptides, extracellular matrix and adhesion molecules, lipids, and growth factors. Elucidating how these pathways operate and how cells respond to these signals is paramount to understanding the nervous system’s function in healthy, neuropsychiatric, and neuropathologic conditions.

The development and widespread adoption of “omics” technologies over the past few decades have made significant contributions to neuroscience research by providing comprehensive insights into the molecular mechanisms of the brain. Genomics, transcriptomics, and proteomics are by far the most widely employed technologies utilized in neuroscience research today and have collectively enhanced our understanding of the molecular mechanisms governing brain functionality, revealing the intricate interplay between genes, their transcripts, and the resultant proteins. However, these technologies do not provide a real-time assessment of the signaling and metabolic pathways in the brain in response to normal and pathological stimuli. This is a critical limitation considering the brain accounts for more than 20% of the human body’s total metabolism while only constituting approximately 2% of our body’s total mass.1 To address this void, the adoption of metabolomics—the study of small molecules known as metabolites—becomes essential. 

Global Metabolomic Profiling in Neuroscience Research

The innate power of omics technologies is in their ability to cast a wide, relatively comprehensive net to identify subtle differences in multiple biological pathways from a single sample. Global untargeted metabolomics, such as Metabolon’s Global Discovery Panel, allows for the simultaneous analysis of thousands of metabolites, including amino acids, lipids, nucleotides, vitamins, and xenobiotics from multiple metabolic pathways such as glycolysis, the citric acid cycle, oxidative stress, fatty acid oxidation, and others. This technology therefore can provide pivotal insight into the current phenotype of a sample and applies to a wide range of neuroscience-related areas of interest (Table 1).2 Moreover, by integrating metabolomics with other omics technologies, researchers can achieve a more holistic view of how genetics and the environment interact to influence neurobiological processes and health outcomes. This integration allows for a comprehensive understanding of the complex interplay between genes, proteins, metabolites, and environmental factors, leading to more effective strategies for neurological disease prevention, diagnosis, and treatment.3

Area of Research PMID Species Tissue Focus
Neurological Disease Etiology, Treatment, and Biomarker Discovery 36251323 Human Brain; Plasma Alzheimer’s Disease
37218097 Human CSF Alzheimer’s Disease
30911576 Human Serum Parkinson’s Disease
32277260 Human Plasma Frontotemporal lobar degeneration
30883584 Human Plasma Post-traumatic Stress Disorder
37495887 Human Plasma Depression
37651185 Human Plasma Glioma
29915278 Rodent Brain Prion Disease
37551969 Human Plasma Traumatic Brain Injury
30867269 Human Serum Ischemic Stroke
Developmental Neuroscience 30577853 Rodent Brain —
33437055 Human CSF —
Liver-Brain Axis 35448538 Rodent Liver; Brain; Serum Encephalopathy
Behavioural and Cognitive Mechanisms 32716356 Human Plasma Cognition
34825649 Rodent Brain Memory
Gut-Brain Axis 35561749 Rodent Brain —

Lipidomic Profiling in Neuroscience Research 

While untargeted metabolomics allows for a wide assessment of the biological changes occurring within the nervous system, lipidomics focuses entirely on lipids, which play a crucial role in the structure and function of the nervous system. It has been estimated that approximately 50% of the human brain’s dry weight is made up of lipids.4 Several classes of lipids are found in the nervous system, including phospholipids, glycolipids, cholesterol and cholesteryl esters, sphingolipids, triacylglycerols (TAGs), eicosanoids, and endocannabinoids. These molecules not only provide structural support for cellular membranes, synapses, and myelin sheaths but can also serve as signaling molecules that help modulate brain development and maintain homeostasis during normal and pathological conditions.5,6 Through lipidomics, researchers can better comprehend brain structure, function, injury processes, and repair mechanisms, offering insights into more effective treatments for brain-related injuries and diseases.7,8

In addition to the Global Discovery Panel, Metabolon also offers quantified lipid analysis capabilities with specialized panels. The Complex Lipids Targeted Panel assesses a range of crucial brain lipids, including phosphatidylcholines, phosphatidylethanolamines, cholesteryl esters, sphingomyelins, and TAGs. Moreover, the Cannabinoids Targeted Panel delivers a detailed quantification of a wide array of cannabinoid compounds, including both endocannabinoids and phytocannabinoids, along with their human metabolites.

The Importance of Study Design 

The unique complexities and limited accessibility of the nervous system, coupled with the difficulties in acquiring various sample types like brain tissue and cerebrospinal fluid (CSF), make the adoption of metabolomics in neuroscience particularly challenging compared to other biological systems. Obtaining CSF, which is often preferred over plasma or serum for its closer representation of the brain’s metabolic environment, is invasive and poses ethical and practical challenges, particularly in vulnerable populations such as children or patients with severe neurological disorders.9 Additionally, the limited volume of CSF that can be safely extracted can also impact data yield. Similarly, the extreme difficulty in acquiring human brain tissue, due to its invasive nature and ethical considerations, further hinders direct studies of human brain metabolism, often limiting analysis to post-mortem samples. Moreover, the heterogeneity of brain tissue, with different anatomical regions having vastly different metabolic profiles, requires precise sampling and adds to the complexity of data interpretation in relation to overall brain function and pathology. Metabolomic analysis of other neuroscience model organisms such as rodents can introduce similar challenges, as the small sizes can severely limit sample volumes, potentially requiring pooled analysis or increased animal numbers.10 This is why we recommend discussing your planned metabolomic analysis with Metabolon scientists in the study design stage so that we can leverage our extensive neuroscience experience and knowledge to achieve an adequately powered and focused analysis tailored to your areas of interest.

References

  1. Raichle ME, Gusnard DA. Appraising the brain’s energy budget. Proc Natl Acad Sci U S A. 2002;99(16):10237-10239. doi:10.1073/pnas.172399499
  2. Vasilopoulou CG, Margarity M, Klapa MI. Metabolomic Analysis in Brain Research: Opportunities and Challenges. Front Physiol. 2016;7:183. doi:10.3389/fphys.2016.00183
  3. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM. Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol. 2008;48:653-683. doi:10.1146/annurev.pharmtox.48.113006.094715
  4. Hamilton JA, Hillard CJ, Spector AA, Watkins PA. Brain uptake and utilization of fatty acids, lipids and lipoproteins: application to neurological disorders. J Mol Neurosci. 2007;33(1):2-11. doi:10.1007/s12031-007-0060-1
  5. Litvinchuk A, Suh JH, Guo JL, et al. Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist. Neuron. 2024;112(3):384-403.e8. doi:10.1016/j.neuron.2023.10.023
  6. Hussain G, Wang J, Rasul A, et al. Role of cholesterol and sphingolipids in brain development and neurological diseases. Lipids Health Dis. 2019;18(1):26. doi:10.1186/s12944-019-0965-z
  7. Yoon JH, Seo Y, Jo YS, et al. Brain lipidomics: From functional landscape to clinical significance. Sci Adv. 2022;8(37):eadc9317. doi:10.1126/sciadv.adc9317
  8. Fitzner D, Bader JM, Penkert H, et al. Cell-Type- and Brain-Region-Resolved Mouse Brain Lipidome. Cell Rep. 2020;32(11):108132. doi:10.1016/j.celrep.2020.108132
  9. Panyard DJ, Kim KM, Darst BF, et al. Cerebrospinal fluid metabolomics identifies 19 brain-related phenotype associations. Commun Biol. 2021;4(1):63. doi:10.1038/s42003-020-01583-z
  10. Chinopoulos C, Zhang SF, Thomas B, Ten V, Starkov AA. Isolation and functional assessment of mitochondria from small amounts of mouse brain tissue. Methods Mol Biol. 2011;793:311-324. doi:10.1007/978-1-61779-328-8_20
Scott Hutton, Ph.D.
Scott is a Senior Study Director within Metabolon’s Discovery and Translational Science (DTS) team. He currently serves as the scientific lead for Metabolon’s Population Health unit, where he leverages his experience in neuroscience, metabolomics, and clinical trial management. By fostering collaborations with academic institutions, healthcare organizations, and industry partners, he ensures that their large-cohort initiatives achieve their scientific and health impact goals.

Topics

Neurology

Share this article

Related Blog Posts

See All Blog Posts

GET STARTED

Talk with an expert

Request a quote, get detailed information on sample types, or learn how metabolomics can accelerate your research. Find our contact details are here.

Find us on:

Talk with a Metabolomics expert

✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.